Howard Hughes Medical Institute, Department of Molecular Biology, Massachusetts General Hospital, United States; Broad Institute of Harvard, MIT, United States; Department of Neurology, Massachusetts General Hospital, United States.
Howard Hughes Medical Institute, Department of Molecular Biology, Massachusetts General Hospital, United States; Broad Institute of Harvard, MIT, United States.
Curr Opin Neurobiol. 2022 Feb;72:80-90. doi: 10.1016/j.conb.2021.09.006. Epub 2021 Oct 14.
Leigh syndrome (LS) is a neurodegenerative disease characterized by bilaterally symmetric brainstem or basal ganglia lesions. More than 80 genes, largely impacting mitochondrial energy metabolism, can underlie LS, and no approved medicines exist. Described 70 years ago, LS was initially diagnosed by the characteristic, necrotic lesions on autopsy. It has been broadly assumed that antemortem neuroimaging abnormalities in these regions correspond to end-stage histopathology. However, clinical observations and animal studies suggest that neuroimaging findings may represent an intermediate state, that is more dynamic than previously appreciated, and even reversible. We review this literature, discuss related conditions that are treatable, and present two new LS cases with radiographic improvement. We review studies in which hypoxia reverses advanced LS in a mouse model. The fluctuating and potentially reversible nature of radiographic LS lesions will be important in clinical trial design. Better understanding of this plasticity could lead to new therapies.
Leigh 综合征(LS)是一种以双侧对称脑桥或基底节病变为特征的神经退行性疾病。80 多个基因,主要影响线粒体能量代谢,可能导致 LS,目前尚无批准的药物。70 年前描述的 LS 最初是通过尸检时特征性的坏死病变来诊断的。人们普遍认为,这些区域的神经影像学异常与终末期组织病理学相对应。然而,临床观察和动物研究表明,神经影像学发现可能代表一种中间状态,比以前认为的更具动态性,甚至是可逆的。我们回顾了这方面的文献,讨论了相关的可治疗的疾病,并介绍了两个新的 LS 病例,这些病例的影像学有改善。我们回顾了在缺氧条件下可逆转小鼠模型中晚期 LS 的研究。影像学 LS 病变的波动性和潜在的可逆性在临床试验设计中很重要。更好地了解这种可塑性可能会导致新的治疗方法。